Format

Send to

Choose Destination
Biomed Res Int. 2013;2013:209735. doi: 10.1155/2013/209735. Epub 2013 Aug 26.

Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion.

Author information

1
Department of Ophthalmology, College of Medicine, Seoul National University Bundang Hospital, 166 Gumiro, Bundang-gu, Seongnam, Gyeonggi-do 463-707, Republic of Korea.

Abstract

PURPOSE:

To compare visual and anatomic outcomes of intravitreal bevacizumab injections administered as needed (PRN group) and initial treatment with 3 monthly injections followed by as-needed injections (3 monthly initial dose group) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

METHODS:

This retrospective study included 69 and 26 patients in the PRN and 3 monthly initial dose groups, respectively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the 2 groups 6 months after initial injection.

RESULTS:

At month 6, BCVA change from baseline was -0.27 ± 0.28 (mean ± standard deviation) logMAR in the PRN group and -0.28 ± 0.20 logMAR in the 3 monthly initial dose group. Mean CRT changes were -204 ± 168 in the PRN group and -161 ± 149  μ m in the 3 monthly initial dose group at month 6. There were no statistically significant differences in BCVA or CRT changes between groups at any time point. The number of intravitreal injections over 6 months was significantly lower in the PRN group (1.8 ± 0.8 injections) than in the 3 monthly initial dose group (3.4 ± 0.5 injections; P < 0.001).

CONCLUSIONS:

Our results suggest that as-needed intravitreal bevacizumab injections are more tolerable for patients with ME secondary to BRVO.

PMID:
24066287
PMCID:
PMC3770007
DOI:
10.1155/2013/209735
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center